Q-omics provides the consensus-scored IFITM5 profile across patient tissues and cancer cell-line models. IFITM5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IFITM5 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, IFITM5 RNA expression shows 10,582 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where IFITM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFITM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFITM5 survival associations across molecular data types. IFITM5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFITM5 RNA expression–survival associations across cancer types. High IFITM5 expression shows unfavorable associations in KIRC, ACC and ESCA, but favorable associations in HNSC, UCS and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for IFITM5 RNA expression.
This table summarizes IFITM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IFITM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFITM5 shows higher tumor expression in COAD, UCEC, HNSC, STAD, LUAD and LIHC. The COAD box plot shows higher IFITM5 RNA expression in tumor versus normal tissue (log2 FC = +0.710, t-test p < 0.001).
This table shows molecular features associated with IFITM5 in patient tissues and cancer cell lines. In patient samples, IFITM5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IFITM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
